8-K filed January 23, 2024, 6:59 PM ET ticker GNVR CIK 0001792941

leadership confidence high sentiment neutral materiality 0.50

Genvor appoints Chad Pawlak CEO, reshuffles executive team; Miller becomes CBO and Interim CFO

Genvor Inc

Chad Pawlak appointed CEO with base salary of $300,000/year and up to 30% annual bonus tied to milestones.
Judith Miller resigns as Interim CEO, becomes CBO and Interim CFO with base salary of $180,000/year plus monthly stock grants.
Dr. Jesse Jaynes named Chief Scientific Officer; Dr. Clayton Yates resigns as CSO and becomes scientific advisor.
Executives receive milestone-based equity: Pawlak eligible for up to 4 million shares upon achieving product and regulatory goals.
Indemnification agreements entered into with all officers and directors effective January 17, 2024.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change (interim)

Judith S. Miller

member of the Board, Chief Business Officer, and Interim Chief Financial Officer

GNVR · Genvor Inc

Effective: 2024-01-17
Successor: Chad Pawlak
Filed: January 23, 2024, 6:59 PM ET

Judith S. Miller resigned as the Company’s Interim Chief Executive Officer and was appointed as a member of the Company’s Board of Directors (the “ Board ”), as the Chief Business Officer of the Company, and as the Interim Chief Financial Officer of the Company

Appointed

Dr. Jesse Jaynes

Chief Scientific Officer

GNVR · Genvor Inc

Effective: 2024-01-17
Filed: January 23, 2024, 6:59 PM ET

Dr. Jesse Jaynes was appointed as the Chief Scientific Officer of the Company

Role change

Dr. Clayton Yates

scientific advisor

GNVR · Genvor Inc

Effective: 2024-01-17
Successor: Dr. Jesse Jaynes
Filed: January 23, 2024, 6:59 PM ET

Dr. Clayton Yates resigned as Chief Scientific Officer of the Company and was appointed as a scientific advisor for the Company

Appointed

Chad Pawlak

Chief Executive Officer

GNVR · Genvor Inc

Effective: 2024-01-17
Filed: January 23, 2024, 6:59 PM ET

Chad Pawlak was appointed as Chief Executive Officer of Genvor Incorporated

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Judith S. Miller was appointed as member of the Board, Chief Business Officer, and Interim Chief Financial Officer at Genvor Inc.

Action: appointed
Role: member of the Board, Chief Business Officer, and Interim Chief Financial Officer

Exact text from the filing

Judith S. Miller resigned as the Company’s Interim Chief Executive Officer and was appointed as a member of the Company’s Board of Directors (the “ Board ”), as the Chief Business Officer of the Company, and as the Interim Chief Financial Officer of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Jesse Jaynes was appointed as Chief Scientific Officer at Genvor Inc.

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

Dr. Jesse Jaynes was appointed as the Chief Scientific Officer of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Clayton Yates was appointed as scientific advisor at Genvor Inc.

Action: appointed
Role: scientific advisor

Exact text from the filing

Dr. Clayton Yates resigned as Chief Scientific Officer of the Company and was appointed as a scientific advisor for the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Chad Pawlak was appointed as Chief Executive Officer at Genvor Inc.

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Chad Pawlak was appointed as Chief Executive Officer of Genvor Incorporated

View on SEC.gov

Genvor Inc filing history →

Source: SEC EDGAR

accession 0001493152-24-003418

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.